BI 2536

Catalog No.S1109

Molecular Weight(MW): 521.66

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

Cited by 131 Publications

Science, 2019, 364(6447)

PubMed: 31249032 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nature, 2017, 548(7668):466-470

PubMed: 28759889 ( click the link to review the publication )

Cancer Discov, 2014, 4(11):1281-9

PubMed: 25107667 ( click the link to review the publication )

Cell, 2011, 4(10):1087-96

PubMed: 22078882 ( click the link to review the publication )

Cancer Cell, 2010, 18(6):641-54

PubMed: 21156286 ( click the link to review the publication )

Cell Res, 2019, 29(7):562-578

PubMed: 31201382 ( click the link to review the publication )

Mol Cell, 2019, 73(5):915-929

PubMed: 30849395 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3779

PubMed: 31439829 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1473

PubMed: 30931927 ( click the link to review the publication )

Nat Commun, 2019, 10(1):993

PubMed: 30824690 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav0318

PubMed: 31803841 ( click the link to review the publication )

Cell Syst, 2019, 8(2):163-167

PubMed: 30797774 ( click the link to review the publication )

Cell Syst, 2019, 9(1):74-92.e8

PubMed: 31302152 ( click the link to review the publication )

EBioMedicine, 2019, 41:244-255

PubMed: 30876762 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):385

PubMed: 31097686 ( click the link to review the publication )

Ther Adv Med Oncol, 2019, 11:1758835919846375

PubMed: 31156720 ( click the link to review the publication )

J Mol Cell Biol, 2019, 10.1093/jmcb/mjz051

PubMed: 31174204 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(9):1615-1627

PubMed: 31227645 ( click the link to review the publication )

FEBS J, 2019, 286(5):963-974

PubMed: 30600590 ( click the link to review the publication )

Mol Cancer Res, 2019, doi: 10

PubMed: 31604847 ( click the link to review the publication )

Lab Invest, 2019, 99(9):1275-1286

PubMed: 30996295 ( click the link to review the publication )

Mol Cell, 2018, 71(1):117-128

PubMed: 30008317 ( click the link to review the publication )
EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Theranostics, 2018, 8(10):2884-2895

PubMed: 29774081 ( click the link to review the publication )

Cancer Res, 2018, 78(2):572-583

PubMed: 29180474 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

Sci Signal, 2018, 11(530)

PubMed: 29764992 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1554-1565

PubMed: 29716963 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(12):2434-2447

PubMed: 30217950 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(11):5300-5310

PubMed: 30133120 ( click the link to review the publication )

Hum Gene Ther, 2018, 29(8):886-901

PubMed: 29641320 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )

Transl Oncol, 2018, 11(4):852-863

PubMed: 29753186 ( click the link to review the publication )

Cell Res, 2017, 27(2):274-293

PubMed: 27958289 ( click the link to review the publication )

Mol Cell, 2017, 67(4):579-593

PubMed: 28781233 ( click the link to review the publication )

Mol Cell, 2017, 68(1):210-223e6

PubMed: 28985505 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1506

PubMed: 29138396 ( click the link to review the publication )

Nat Commun, 2017, 8:15289

PubMed: 28474672 ( click the link to review the publication )

Aging Cell, 2017, 16(3):575-584

PubMed: 28345297 ( click the link to review the publication )

FASEB J, 2017, 32(2):625-638

PubMed: 28970258 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(2):431-444

PubMed: 28922657 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):3-15

PubMed: 27760837 ( click the link to review the publication )

FEBS J, 2017, 284(23):4035-4050

PubMed: 28985013 ( click the link to review the publication )

J Biol Chem, 2017, 292(36):15028-15038

PubMed: 28739871 ( click the link to review the publication )

Cell Signal, 2017, 39:74-83

PubMed: 28780319 ( click the link to review the publication )
Am J Physiol Cell Physiol, 2017, 313(5):C501-C515

PubMed: 28794108 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 484(4):864-870

PubMed: 28188792 ( click the link to review the publication )

Oncotarget, 2017, 9(13):10920-10933

PubMed: 29541386 ( click the link to review the publication )

Oncotarget, 2017, 8(23):37633-37645

PubMed: 28430578 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2017

PubMed: 26829474 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Nat Commun, 2016, 7:10818

PubMed: 26912231 ( click the link to review the publication )

Nat Chem Biol, 2016, 12(6):411-8

PubMed: 27043190 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(1):48-59

PubMed: 26586723 ( click the link to review the publication )

J Virol, 2016, 90(6):2794-805

PubMed: 26719254 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M116.722751

PubMed: 27226586 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M115.712745

PubMed: 27325694 ( click the link to review the publication )

J Biol Chem, 2016, 291(20):10904-15

PubMed: 27002159 ( click the link to review the publication )

Cell Cycle, 2016, 15(15):2009-18

PubMed: 27249336 ( click the link to review the publication )

PLoS One, 2016, 11(4):e0153818

PubMed: 27097159 ( click the link to review the publication )

Head Neck, 2016, 10.1002/hed.24349

PubMed: 26713885 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: 25599390 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(1):31-43

PubMed: 25503564 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(8):1024-35

PubMed: 26192437 ( click the link to review the publication )

Nat Commun, 2015, 6:8388

PubMed: 26399523 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms8217

PubMed: 26147444 ( click the link to review the publication )

Nat Commun, 2015, 6:6891

PubMed: 25922916 ( click the link to review the publication )
Nat Commun, 2015, 6:8077

PubMed: 26293378 ( click the link to review the publication )

Nat Commun, 2015, 6:6946

PubMed: 25897860 ( click the link to review the publication )

Nat Commun, 2015, 6:10076

PubMed: 26647647 ( click the link to review the publication )

Nat Commun, 2015, 6:10072

PubMed: 26656453 ( click the link to review the publication )

Cancer Res, 2015, 75(2):405-14

PubMed: 25480943 ( click the link to review the publication )

J Control Release, 2015, 204:20-29

PubMed: ( click the link to review the publication )

Cancer Lett, 2015, 357(2):591-601

PubMed: 25524551 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 14(4):946-60

PubMed: 25659891 ( click the link to review the publication )

J Neurochem, 2015, 10.1111/jnc.13085

PubMed: 25727910 ( click the link to review the publication )

J Biol Chem, 2015, 290(5):3033-44

PubMed: 25505268 ( click the link to review the publication )

Mol Biol Cell, 2015, 26(3):440-52

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(2):219-31

PubMed: 25607646 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2315-30

PubMed: 25537513 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5275-91

PubMed: 25779659 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2315-30

PubMed: 25537513 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(6):538-49

PubMed: 24776885 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(12):3211-21

PubMed: 24771642 ( click the link to review the publication )

Cancer Res, 2014, 74(20):5878-90

PubMed: 25125659 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(5):1160-71

PubMed: 24568369 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 13(5):1054-66

PubMed: 24748653 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26344-56

PubMed: 25100726 ( click the link to review the publication )

J Biol Chem, 2014, 289(18):12313-29

PubMed: 24634213 ( click the link to review the publication )

J Biol Chem, 2014, 289,14066-14074

PubMed: ( click the link to review the publication )
J Biol Chem, 2014, 289(20):14066-74

PubMed: 24706748 ( click the link to review the publication )

Cell Cycle, 2014, 13(2):303-14

PubMed: 24247149 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3867-77

PubMed: 25558830 ( click the link to review the publication )

Cell Cycle, 2014, 13(14):2248-61

PubMed: 24875404 ( click the link to review the publication )

Biosci Rep, 2014, 34(3)

PubMed: 24844881 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115228

PubMed: 25542032 ( click the link to review the publication )

PLoS One, 2014, 8(10):e77053

PubMed: 24204733 ( click the link to review the publication )

Oncotarget, 2014, 5(3):667-78

PubMed: 24525428 ( click the link to review the publication )

The University of Queensland, 2014, Fawzi Faisal A. Bokhari

PubMed: ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(32):13026-31

PubMed: 23878225 ( click the link to review the publication )

Cancer Res, 2013, 73(22):6722-33

PubMed: 24101154 ( click the link to review the publication )

Cancer Res, 2013, 73(2):813-23

PubMed: 23144294 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Oncogene, 2013, 10.1038/onc.2013.518

PubMed: 24317508 ( click the link to review the publication )

Br J Cancer, 2013, 110(2):510-9

PubMed: 24327015 ( click the link to review the publication )

Gynecol Oncol, 2013, 128(3):461-9

PubMed: 23146687 ( click the link to review the publication )

J Biol Chem, 2013, 288(33):23765-75

PubMed: 23814058 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14158-69

PubMed: 23504319 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2013, 54(13):8353-63

PubMed: 24366665 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(5):436-49

PubMed: 23377828 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77390

PubMed: 24155950 ( click the link to review the publication )

J Biomol Screen, 2013, 18(1):54-66

PubMed: 22923784 ( click the link to review the publication )

Biol Open, 2013, 2(5):479-86

PubMed: 23789096 ( click the link to review the publication )

J Biol Chem, 2012, 287(6):4376-85

PubMed: 22184120 ( click the link to review the publication )
J Biol Chem, 2012, 287(21):17088-99

PubMed: 22467873 ( click the link to review the publication )

Cell Cycle, 2012, 11(3):543-53

PubMed: 22262171 ( click the link to review the publication )

PLoS One, 2012, 7(6):e38838

PubMed: 22701722 ( click the link to review the publication )

Biotechniques, 2012, 10.2144/000113866

PubMed: ( click the link to review the publication )

Biotechniques, 2012, 53(1)

PubMed: 26307252 ( click the link to review the publication )

Nat Cell Biol, 2011, 13(10):1265-71

PubMed: 21874008 ( click the link to review the publication )

Cancer Res, 2011, 71(4):1385-95

PubMed: 21303981 ( click the link to review the publication )

Cancer Res, 2011, 71(17):5659-69

PubMed: 21693658 ( click the link to review the publication )

J Cell Biol, 2011, 193(6):1083-99

PubMed: 21646404 ( click the link to review the publication )

Oncogene, 2011, 30(46):4666-77

PubMed: 21602893 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(9):1886-95

PubMed: 21654832 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Description

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

Features

The first potent and selective Plk1 inhibitor that induces all hallmarks of Plk1 inhibition.

Targets

PLK1 ^[1] (Cell-free assay)	PLK2 ^[1] (Cell-free assay)	PLK3 ^[1] (Cell-free assay)
0.83 nM	3.5 nM	9.0 nM

In vitro

BI 2536 blocks the activities of Plk2 and Plk3 to a slightly lesser extent with IC50 of 3.5 nM and 9.0 nM, respectively. In HeLa cells, BI 2536 treatment ranging from 10-100 nM leads to the blocking of the recruitment of γ-tubulin and phosphorylation of Apc6 at mitotic centrosomes, inhibition of cohesin release from chromosome arms, induction of monopolar spindles, as well as a range of other mitotic processes that are known to depend on Plk1. BI 2536 treatment leads to the HeLa cells arrested in G2/M, subsequently a sub-G1 DNA peak indicative of DNA breakdown and apoptosis, and accumulated cleaved PARP p85 fragments in a concentration-dependent manner. BI 2536 inhibits the growth of a panel of 32 human cancer cell lines with EC50 of 2-25 nM, while blocking the proliferation of exponentially growing hTERT-RPE1, human umbilical vein endothelial cells (HUVECs), and normal rat kidney (NRK) cells with EC50 of 12-31 nM. ^[1] Plk1 inhibition by BI 2536 reduces the growth and viability of anaplastic thyroid carcinoma (ATC) cells such as CAL62, OCUT-1, SW1736, 8505C, and ACT-1 with EC50 values of 1.4-5.6 nM. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PSN1	M1rLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TSfWlEPTB;MD6wNFc4PiEQvF2=	NGftSYtUSU6JRWK=
ACN	NGHQXllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fQSmlEPTB;MD6wNFg1OyEQvF2=	NVjkZm97W0GQR1XS
TE-8	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPE[4U5UUN3ME2wMlAxQTRzIN88US=>	MnjDV2FPT0WU
LC-2-ad	MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\sRXpKSzVyPUCuNFExQTNizszN	Mm\0V2FPT0WU
ALL-PO	M3zHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTBwMEGzJO69VQ>?	NUPvPJc{W0GQR1XS
EW-16	NV3ib3RMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfQO25KSzVyPUCuNFE{OzZizszN	M3r1dHNCVkeHUh?=
KM12	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHv[nNKSzVyPUCuNFE{PDhizszN	MoHIV2FPT0WU
GI-1	Ml;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHITWM2OD1yLkCxN\|g{KM7:TR?=	MWfTRW5ITVJ?
LS-411N	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3f5NmlEPTB;MD6wNVQxPyEQvF2=	NXTOcXFFW0GQR1XS
ES8	MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\1TWM2OD1yLkCxOFk1KM7:TR?=	NI\hRVlUSU6JRWK=
SNU-C2B	NXHkelRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzYTWM2OD1yLkCxOVI3KM7:TR?=	NGPuT4tUSU6JRWK=
CESS	NHSzNJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTJTWM2OD1yLkCxOlAzKM7:TR?=	M{D2V3NCVkeHUh?=
697	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTBwMEG2Olgh\|ryP	M4HNTHNCVkeHUh?=
NCI-H1963	M{Xwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTBwMEG2O\|Mh\|ryP	MknlV2FPT0WU
IA-LM	NUPydpJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrT[W5nUUN3ME2wMlAyPjh6IN88US=>	NYqzeFBZW0GQR1XS
SW954	NID2TG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzVTWM2OD1yLkCxO\|A2KM7:TR?=	M4jPUHNCVkeHUh?=
RL95-2	NYnsc3hCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\ReWtuUUN3ME2wMlAyPzN6IN88US=>	MV;TRW5ITVJ?
LXF-289	M4LneGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1fMXmlEPTB;MD6wNVc4KM7:TR?=	NGTQO\|RUSU6JRWK=
OCUB-M	M3faSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PlRWlEPTB;MD6wNVgzPiEQvF2=	NGLzfZFUSU6JRWK=
RKO	NIDBe5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXO[nhUUUN3ME2wMlAyQTh5IN88US=>	M3XIXnNCVkeHUh?=
LOUCY	MlS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LOdWlEPTB;MD6wNlA2KM7:TR?=	MVvTRW5ITVJ?
NOS-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\jTWM2OD1yLkCyNFk{KM7:TR?=	M1q1UnNCVkeHUh?=
A4-Fuk	M4XsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3foOmlEPTB;MD6wNlIyQCEQvF2=	M3;1[nNCVkeHUh?=
A388	MkHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnXOXBKSzVyPUCuNFIzOjdizszN	NF7BUWRUSU6JRWK=
TE-9	M{PVUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHK2UGxKSzVyPUCuNFIzPjFizszN	MXnTRW5ITVJ?
KURAMOCHI	M1HIdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\PUGJHUUN3ME2wMlAzOjh3IN88US=>	MkLGV2FPT0WU
KALS-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjkTWM2OD1yLkCyN\|M5KM7:TR?=	Moq0V2FPT0WU
HOP-62	MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnSd3lKSzVyPUCuNFI1OiEQvF2=	M3i1c3NCVkeHUh?=
RPMI-8402	NGXRfVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF34fJBKSzVyPUCuNFI2ODhizszN	NIDMOmRUSU6JRWK=
TE-1	Ml;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTBwMEK1NVIh\|ryP	NHHJ[2pUSU6JRWK=
CCRF-CEM	NVGzdGtHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTBwMEK1OFMh\|ryP	MofYV2FPT0WU
HUTU-80	MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{niPGlEPTB;MD6wNlYzPCEQvF2=	NGfJXYtUSU6JRWK=
NCI-H1648	NIOxc4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXQeJlnUUN3ME2wMlAzPjR5IN88US=>	M2j2VHNCVkeHUh?=
HCE-4	M2TpZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DXfGlEPTB;MD6wNlY5OiEQvF2=	NFe5UZJUSU6JRWK=
ETK-1	Mny5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\V[2lEPTB;MD6wNlc{PiEQvF2=	NUjJ[WVIW0GQR1XS
TE-15	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2Tsc2lEPTB;MD6wNlc{QCEQvF2=	M{WydnNCVkeHUh?=
BE-13	M1TtRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTBwMEK3OEDPxE1?	M2\SfnNCVkeHUh?=
KE-37	M1Tpd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHjTWM2OD1yLkCyO\|QyKM7:TR?=	MWfTRW5ITVJ?
NCI-H1355	NE\LWYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MormTWM2OD1yLkCyO\|g{KM7:TR?=	MmnUV2FPT0WU
TE-11	NIHQd4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVH5ZWpxUUN3ME2wMlAzQDB7IN88US=>	NUPDW5RXW0GQR1XS
BL-70	M2rKSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYOzNYxOUUN3ME2wMlAzQDV5IN88US=>	MlHsV2FPT0WU
ES6	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXL2VoZ2UUN3ME2wMlAzQDhzIN88US=>	NVfRdVJSW0GQR1XS
GT3TKB	NGTqVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTBwMEK5OVMh\|ryP	MV\TRW5ITVJ?
LB647-SCLC	NWLlTY1oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NESxUoFKSzVyPUCuNFMyQTVizszN	MVLTRW5ITVJ?
NB13	MnT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTBwMEOzNVYh\|ryP	MneyV2FPT0WU
ST486	M1PucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknZTWM2OD1yLkCzN\|M4KM7:TR?=	M1;Ne3NCVkeHUh?=
NCI-H82	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTBwMEOzOFMh\|ryP	MXjTRW5ITVJ?
NTERA-S-cl-D1	M{HT[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XOWGlEPTB;MD6wN\|M6QSEQvF2=	M4jObHNCVkeHUh?=
ES4	NVz2UodIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4m0RWlEPTB;MD6wN\|Q3OyEQvF2=	NH\VeIJUSU6JRWK=
SK-NEP-1	NFXK[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYD1VpFuUUN3ME2wMlA{PDl7IN88US=>	M2HuTHNCVkeHUh?=
Becker	NXXic3VGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDETWM2OD1yLkCzOVU2KM7:TR?=	NHriVJNUSU6JRWK=
A101D	M3KxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTBwMEO3OFgh\|ryP	MVPTRW5ITVJ?
SK-UT-1	NFHVZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTBwMEO3O\|Qh\|ryP	MmrzV2FPT0WU
SW982	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTBwMEO3PUDPxE1?	MoHmV2FPT0WU
TE-10	NWHoR246T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HF[WlEPTB;MD6wOFA1PiEQvF2=	NXW5WYszW0GQR1XS
OVCAR-4	NI\3cY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVi1cJdSUUN3ME2wMlA1ODV7IN88US=>	NXHFVVVmW0GQR1XS
KP-N-YS	NWXBNHoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLhUpBDUUN3ME2wMlA1ODh3IN88US=>	M3;s[nNCVkeHUh?=
BL-41	MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn6zTWM2OD1yLkC0NVI2KM7:TR?=	NYLwNo9DW0GQR1XS
MZ1-PC	NVTsXFJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlu3TWM2OD1yLkC0NVI4KM7:TR?=	NHewOYtUSU6JRWK=
PF-382	NWT6SItOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mom5TWM2OD1yLkC0NVk5KM7:TR?=	M1jBfXNCVkeHUh?=
MOLT-13	NX;SUnlqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUGwVY5HUUN3ME2wMlA1OjN6IN88US=>	NH2xd4pUSU6JRWK=
HCC1599	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTBwMESyOVgh\|ryP	MlTXV2FPT0WU
IST-MEL1	Mm\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{H3bGlEPTB;MD6wOFQ1OiEQvF2=	MlX3V2FPT0WU
LU-139	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljLTWM2OD1yLkC0OFQzKM7:TR?=	NFvTZYhUSU6JRWK=
MS-1	MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILTO\|FKSzVyPUCuNFQ4ODFizszN	MmXLV2FPT0WU
MFH-ino	M2XNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWmxXHh[UUN3ME2wMlA2ODB\|IN88US=>	NIq0PVlUSU6JRWK=
IMR-5	MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HCXWlEPTB;MD6wOVAzOSEQvF2=	NIjqXYJUSU6JRWK=
TE-5	NV;3fIVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfabXdKSzVyPUCuNFUxPjNizszN	M1L5XnNCVkeHUh?=
DJM-1	NYrWZmtiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGWwOXJKSzVyPUCuNFUyPDJizszN	M1rtSnNCVkeHUh?=
NB17	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTBwMEWyNFch\|ryP	NHLsVZZUSU6JRWK=
KARPAS-45	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvLNHAxUUN3ME2wMlA2OzV6IN88US=>	NFzZNGxUSU6JRWK=
TGBC1TKB	M37Y[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVm3bZFpUUN3ME2wMlA2PDB3IN88US=>	M3TvdHNCVkeHUh?=
ML-2	M{naW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\hXlVKSzVyPUCuNFU1OTRizszN	M2rlcnNCVkeHUh?=
no-10	NHzabGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPVTWM2OD1yLkC1OFc1KM7:TR?=	MkLXV2FPT0WU
CTV-1	MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\QVohKSzVyPUCuNFU2ODJizszN	NVnjd49DW0GQR1XS
SJSA-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3fwV2lEPTB;MD6wOVUzKM7:TR?=	M4Tx[HNCVkeHUh?=
HC-1	NWS2[Y9GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTBwMEW1PVch\|ryP	NH;vN2hUSU6JRWK=
TE-12	M2POeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTxTWM2OD1yLkC1OlE{KM7:TR?=	MmXMV2FPT0WU
KY821	NXK5bIZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfMV3d5UUN3ME2wMlA2PjN{IN88US=>	NHHCenJUSU6JRWK=
TALL-1	NITBRotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYf1WGlRUUN3ME2wMlA2PzB6IN88US=>	M1[yU3NCVkeHUh?=
DEL	NHHFW2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLQTWM2OD1yLkC1O\|A6KM7:TR?=	NEj6XlhUSU6JRWK=
TE-6	M2j2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\qc5JKSzVyPUCuNFU4OjJizszN	NVfOemZSW0GQR1XS
SK-LMS-1	NYW1S4V{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml71TWM2OD1yLkC1PFA2KM7:TR?=	M2GxNnNCVkeHUh?=
EW-1	M3zScmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPlT4ZuUUN3ME2wMlA2QDN5IN88US=>	M3zSTXNCVkeHUh?=
8-MG-BA	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjle2RqUUN3ME2wMlA2QDVzIN88US=>	NEDWdYtUSU6JRWK=
NALM-6	NFizT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjxVI5KSzVyPUCuNFU6PzNizszN	M4[3b3NCVkeHUh?=
LB771-HNC	NF65SmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjU[GVDUUN3ME2wMlA2QTd7IN88US=>	NWT2WmROW0GQR1XS
HT-144	NGHkWGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\JNmlEPTB;MD6wOlE{KM7:TR?=	M1vJPXNCVkeHUh?=
KM-H2	M3jhd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\YS2VjUUN3ME2wMlA3OjJzIN88US=>	NGHGS2xUSU6JRWK=
SF268	NW\VVopRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPMVGFPUUN3ME2wMlA3Ojh4IN88US=>	MkXqV2FPT0WU
RS4-11	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVi3foNUUUN3ME2wMlA3OzB2IN88US=>	MljwV2FPT0WU
MHH-PREB-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYH2UZR4UUN3ME2wMlA3OzF7IN88US=>	MmLLV2FPT0WU
ATN-1	M2jnb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrUfVdKSzVyPUCuNFY{PDVizszN	M4PNRXNCVkeHUh?=
BB30-HNC	MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzGTWM2OD1yLkC2OFM3KM7:TR?=	MlrHV2FPT0WU
CPC-N	MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;IR2lEPTB;MD6wOlUzPCEQvF2=	NFnOToZUSU6JRWK=
NB1	MlTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDRWld5UUN3ME2wMlA3PjF\|IN88US=>	MUnTRW5ITVJ?
KS-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTBwME[3OFgh\|ryP	NFuxOYRUSU6JRWK=
RXF393	NWjMVHJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX74cHVUUUN3ME2wMlA3PzZ2IN88US=>	NVTGWHh7W0GQR1XS
IST-SL2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTBwMEewNFQh\|ryP	NEnC[FNUSU6JRWK=
GI-ME-N	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjISm5KSzVyPUCuNFczQDZizszN	MVTTRW5ITVJ?
VA-ES-BJ	NYe2UXhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXnTWM2OD1yLkC3OFc2KM7:TR?=	NFu1c5JUSU6JRWK=
NCI-H1581	M{LIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvUeIVKSzVyPUCuNFc1PzhizszN	MVXTRW5ITVJ?
U-266	NIDqRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvMTWM2OD1yLkC3OFk4KM7:TR?=	MYTTRW5ITVJ?
DMS-114	NGjEcnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTBwMEe1Nlgh\|ryP	M1e0ZnNCVkeHUh?=
NCI-H187	NF\tOJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1H6V2lEPTB;MD6wO\|czPiEQvF2=	M37COHNCVkeHUh?=
SW962	NVzib2RjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2qxVGlEPTB;MD6wO\|g{QSEQvF2=	MkW2V2FPT0WU
MONO-MAC-6	M3P1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\XUIZKSzVyPUCuNFc6QDZizszN	NGG5enRUSU6JRWK=
MOLT-16	M2eyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFO5UJdKSzVyPUCuNFgyOjFizszN	MXnTRW5ITVJ?
KNS-42	Mnq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1r5O2lEPTB;MD6wPFE3OSEQvF2=	MlTjV2FPT0WU
CMK	M2rEOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPtTWM2OD1yLkC4NlI2KM7:TR?=	NXHnWWtZW0GQR1XS
Ramos-2G6-4C10	M1Hmfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHTHSoNKSzVyPUCuNFgzOjVizszN	NEfTXpJUSU6JRWK=
Daudi	M3rMemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PtW2lEPTB;MD6wPFI2PiEQvF2=	M{nKZ3NCVkeHUh?=
NCI-H510A	M4W1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rnXGlEPTB;MD6wPFM{PiEQvF2=	MXXTRW5ITVJ?
LB831-BLC	NHGwc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTBwMEi1OlEh\|ryP	M4q5NXNCVkeHUh?=
HEL	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGG5T2VKSzVyPUCuNFg3PjhizszN	MmGyV2FPT0WU
LU-134-A	M3zxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTBwMEi3NFgh\|ryP	MnX4V2FPT0WU
NCI-H1694	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTBwMEi3OFQh\|ryP	MWXTRW5ITVJ?
KGN	M1:1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPsbo43UUN3ME2wMlA5PzV7IN88US=>	NHrGbYdUSU6JRWK=
A253	NHTDS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTBwMEi4NlIh\|ryP	MlO3V2FPT0WU
DG-75	M3HST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXnLZ3RGUUN3ME2wMlA5QTJ{IN88US=>	M4rCV3NCVkeHUh?=
MOLT-4	MkfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTBwMEi5PFMh\|ryP	MYnTRW5ITVJ?
NCI-SNU-5	MnrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTvTWM2OD1yLkC5NlU5KM7:TR?=	M{C0NXNCVkeHUh?=
ONS-76	Mm[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;nUHRnUUN3ME2wMlA6Ojd4IN88US=>	NFLOUXpUSU6JRWK=
NCI-H446	M1q1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTBwMEm0OlIh\|ryP	NVHWTWplW0GQR1XS
COR-L279	NX\jd5ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYX4bW1mUUN3ME2wMlA6PTV4IN88US=>	MWDTRW5ITVJ?
Calu-6	M1rsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTBwMEm1PVgh\|ryP	M{LFWnNCVkeHUh?=
BC-3	M4HlS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHmTWM2OD1yLkC5OlYzKM7:TR?=	MmXxV2FPT0WU
NCI-H2126	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoH5TWM2OD1yLkC5O\|kyKM7:TR?=	NFrOPYFUSU6JRWK=
NCI-H1882	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPKXYFkUUN3ME2wMlA6QDB7IN88US=>	M1jwT3NCVkeHUh?=
BB65-RCC	M3Lifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjpTWM2OD1yLkGwNlk1KM7:TR?=	NGHQPYlUSU6JRWK=
DU-4475	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zqcGlEPTB;MD6xNFQxPyEQvF2=	MnfCV2FPT0WU
NCI-H526	MmriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLlTWM2OD1yLkGwOFQh\|ryP	M{HnSnNCVkeHUh?=
NEC8	Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTBwMUC1NlUh\|ryP	NGPWPWRUSU6JRWK=
NCI-H1304	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFOxOGFKSzVyPUCuNVA2QTRizszN	MoTHV2FPT0WU
L-540	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGW2UIhKSzVyPUCuNVA4ODhizszN	MUXTRW5ITVJ?
NCI-SNU-16	NIPZWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfYVZRGUUN3ME2wMlExPzR{IN88US=>	MlvOV2FPT0WU
HD-MY-Z	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnafYdVUUN3ME2wMlExQDV4IN88US=>	M1;wOHNCVkeHUh?=
K-562	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\tfHBvUUN3ME2wMlExQDV6IN88US=>	NVzOdJM6W0GQR1XS
JAR	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTBwMUC5NlUh\|ryP	M3;1OHNCVkeHUh?=
MZ2-MEL	NXHNc2IzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTBwMUGwOUDPxE1?	NF;UWlFUSU6JRWK=
L-363	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3YTWM2OD1yLkGxNFc6KM7:TR?=	NX\1SYdDW0GQR1XS
BV-173	NYCwb5l4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LYOGlEPTB;MD6xNVI1OyEQvF2=	NVLhR4djW0GQR1XS
NCI-H524	NIXhUm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlm1TWM2OD1yLkGxNlc1KM7:TR?=	NHi0VXBUSU6JRWK=
EoL-1-cell	NYryfIRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\K[VRrUUN3ME2wMlEyPjd{IN88US=>	NHTuWoNUSU6JRWK=
K052	NHr0XIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnz[WVGUUN3ME2wMlEyPzF{IN88US=>	NWjxe\|hrW0GQR1XS
TK10	NVrke\|VOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XCUWlEPTB;MD6xNVczQCEQvF2=	MUDTRW5ITVJ?
KU812	NF\4VoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PKUGlEPTB;MD6xNlA1PCEQvF2=	NHu3cmJUSU6JRWK=
RPMI-8226	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\UTFRnUUN3ME2wMlEzODV{IN88US=>	Mli0V2FPT0WU
MZ7-mel	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vqe2lEPTB;MD6xNlI{PyEQvF2=	MWTTRW5ITVJ?
SK-PN-DW	NIm0TmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LyO2lEPTB;MD6xNlI5PyEQvF2=	NXW5cpFCW0GQR1XS
SR	NVH5OpZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2r3fWlEPTB;MD6xNlQ1OSEQvF2=	M4jZb3NCVkeHUh?=
RPMI-6666	M3LIemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojFTWM2OD1yLkGyO\|Q{KM7:TR?=	MlLUV2FPT0WU
no-11	MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;lXFJKSzVyPUCuNVI5PjlizszN	NXr2cmdTW0GQR1XS
EW-3	M4CySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;tTWM2OD1yLkGyPFk{KM7:TR?=	MX3TRW5ITVJ?
LAMA-84	NGPpPIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTBwMUOxPFch\|ryP	NXntcJllW0GQR1XS
HT	NX3CdY9wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHK1NVJKSzVyPUCuNVM2PzRizszN	M{XzUXNCVkeHUh?=
KP-N-RT-BM-1	NILI[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13UVmlEPTB;MD6xN\|YyOiEQvF2=	NVXBd5NLW0GQR1XS
NCI-H747	M{f2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTBwMUO3JO69VQ>?	M{\wSnNCVkeHUh?=
NCCIT	Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTBwMUO5N\|kh\|ryP	NXT3Z4FiW0GQR1XS
MLMA	M{G5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTBwMUSxOlch\|ryP	NGDUVlFUSU6JRWK=
LP-1	MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XKcWlEPTB;MD6xOFI1KM7:TR?=	M1nVTXNCVkeHUh?=
CAL-148	Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\VS\|FnUUN3ME2wMlE1PDh\|IN88US=>	NYWzfFAyW0GQR1XS
GB-1	NXjIVpFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDofJZKSzVyPUCuNVQ2OjZizszN	M2\XcXNCVkeHUh?=
COR-L88	NWTue4tVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\DTWM2OD1yLkG0PFAzKM7:TR?=	NXy3[FhoW0GQR1XS
NKM-1	NG\SOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTDTWM2OD1yLkG0PVA3KM7:TR?=	M13xWnNCVkeHUh?=
NB5	M1Tk[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1[ydWlEPTB;MD6xOVQ3OiEQvF2=	NIH0TmZUSU6JRWK=
SH-4	M4TMTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTBwMUW0OlYh\|ryP	NUSz[no6W0GQR1XS
EM-2	MkP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIH4UnNKSzVyPUCuNVU1PjdizszN	NXrYXoVLW0GQR1XS
TGBC24TKB	NH32PZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjvVFgyUUN3ME2wMlE2PjV7IN88US=>	NIHvflVUSU6JRWK=
SCLC-21H	NWfmN4JMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPOUmdKSzVyPUCuNVU4ODJizszN	NXS2NlJTW0GQR1XS
COLO-684	MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXvVod5UUN3ME2wMlE2PzJzIN88US=>	NI[weZZUSU6JRWK=
KINGS-1	MlHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUe0dIRrUUN3ME2wMlE2QTFizszN	NGKxTo9USU6JRWK=
LS-123	NXPBcmJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4Lub2lEPTB;MD6xOVkyPyEQvF2=	NGP1O4ZUSU6JRWK=
MC116	M4P6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XVeGlEPTB;MD6xOlE2QCEQvF2=	MUDTRW5ITVJ?
SU-DHL-1	MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;QTWM2OD1yLkG2NlA3KM7:TR?=	M{[1XXNCVkeHUh?=
NCI-H64	NH7zc3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTBwMU[zOFch\|ryP	MXjTRW5ITVJ?
HCE-T	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrQTWM2OD1yLkG2OVA1KM7:TR?=	MUjTRW5ITVJ?
LOXIMVI	M2Dwdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrQVIRqUUN3ME2wMlE3QTR7IN88US=>	M2TCS3NCVkeHUh?=
ARH-77	NGjuNnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DNSmlEPTB;MD6xO\|M4QSEQvF2=	NVHpTmRuW0GQR1XS
DOHH-2	NI\HWWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnj[lF5UUN3ME2wMlE4Pjd{IN88US=>	MWLTRW5ITVJ?
COLO-320-HSR	M1vEWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXITWM2OD1yLkG4NVU1KM7:TR?=	MWXTRW5ITVJ?
NB6	MkPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIjrT2VKSzVyPUCuNVg2PjZizszN	NUXZPVB[W0GQR1XS
L-428	NF3ZZVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDHOZViUUN3ME2wMlE5QDF\|IN88US=>	M{nZenNCVkeHUh?=
SNB75	Mlj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\OS2lEPTB;MD6xPFgzPCEQvF2=	NGfQeXpUSU6JRWK=
NCI-H2141	NWPZNFJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTBwMUmwNVEh\|ryP	M3;JSHNCVkeHUh?=
KARPAS-299	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTBwMUmyOFEh\|ryP	NXTIUoV{W0GQR1XS
LC4-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjqVoRMUUN3ME2wMlE6PTB{IN88US=>	M{\GPXNCVkeHUh?=
UACC-257	MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWXtOYVkUUN3ME2wMlE6QTR5IN88US=>	MXzTRW5ITVJ?
EVSA-T	NF;4fVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnqeHVKSzVyPUCuNlA{OTJizszN	NHKxVFVUSU6JRWK=
JiyoyeP-2003	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTBwMkC0O\|ch\|ryP	M2rhSXNCVkeHUh?=
NCI-H720	MmPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTBwMkC1NlUh\|ryP	Mlz6V2FPT0WU
GAK	M1zrTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITxSWZKSzVyPUCuNlEyQDlizszN	NEm2TXpUSU6JRWK=
HH	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDQZWpyUUN3ME2wMlIyPDB3IN88US=>	MmPkV2FPT0WU
NCI-H1436	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTBwMkG0OlQh\|ryP	Ml3ZV2FPT0WU
GR-ST	Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPqWo5KSzVyPUCuNlE1QDhizszN	MkLDV2FPT0WU
BC-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUP6XJF1UUN3ME2wMlIzPjF4IN88US=>	NIPHZ5FUSU6JRWK=
SIG-M5	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnS5TWM2OD1yLkKyO\|I4KM7:TR?=	MX\TRW5ITVJ?
NCI-H345	M{H5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3RZ\|d2UUN3ME2wMlI{QDB3IN88US=>	NUTmbVhoW0GQR1XS
OPM-2	MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfwPFJIUUN3ME2wMlI{QDh{IN88US=>	MoHqV2FPT0WU
LB1047-RCC	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTBwMkS0NUDPxE1?	MlHxV2FPT0WU
CTB-1	NHHBc2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTBwMkS0PVMh\|ryP	NX21VoxnW0GQR1XS
A3-KAW	NH7Zb2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLNeXl{UUN3ME2wMlI2OzRzIN88US=>	M{Dye3NCVkeHUh?=
SF126	M1nWNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnXflRKSzVyPUCuNlU{QDNizszN	NGL0cXZUSU6JRWK=
KARPAS-422	M32xXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nNb2lEPTB;MD6yOVQ{PSEQvF2=	NH:2O3FUSU6JRWK=
MEG-01	M3PWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTrfWlTUUN3ME2wMlI2Pjd\|IN88US=>	NWToNHJ1W0GQR1XS
NCI-H209	NYmwW4VjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTBwMk[zO\|Qh\|ryP	MVfTRW5ITVJ?
SBC-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzGZoplUUN3ME2wMlI3PSEQvF2=	MlLlV2FPT0WU
K5	NYHkUWhMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1m3bWlEPTB;MD6yOlk5PCEQvF2=	NXLzSI5ZW0GQR1XS
QIMR-WIL	M4\6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rjeWlEPTB;MD6yO\|E2PSEQvF2=	NXf4O\|dSW0GQR1XS
NMC-G1	MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTBwMkiyNVch\|ryP	NFzvdoZUSU6JRWK=
IST-MES1	M{DFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlH5TWM2OD1yLkK5NlM5KM7:TR?=	NGW5Nm5USU6JRWK=
SW684	NYTJR3h[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37xcGlEPTB;MD6zNFA1PyEQvF2=	M4izOXNCVkeHUh?=
MV-4-11	NYfhVZRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTBwM{C3PFgh\|ryP	MVzTRW5ITVJ?
LAN-6	M4fDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTBwM{G1O\|Ih\|ryP	MYrTRW5ITVJ?
RH-1	NGDScIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\1VWlEPTB;MD6zNVg4OSEQvF2=	MV3TRW5ITVJ?
CP66-MEL	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTBwM{G4O\|gh\|ryP	MlqyV2FPT0WU
EC-GI-10	M1q3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXrEfXVbUUN3ME2wMlMzQTh5IN88US=>	MnzGV2FPT0WU
GDM-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmr1TWM2OD1yLkOzNFU6KM7:TR?=	NEfWVHNUSU6JRWK=
IST-SL1	NY\heJc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTBwM{S5NVQh\|ryP	MmDRV2FPT0WU
KMOE-2	NYHXcVI1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXm2fGR6UUN3ME2wMlM2OTd3IN88US=>	Mm\PV2FPT0WU
OS-RC-2	NHXuWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF;kZoNKSzVyPUCuN\|U2PDRizszN	MWXTRW5ITVJ?
HDLM-2	MmnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHLTWM2OD1yLkO3PFE1KM7:TR?=	M{e3Z3NCVkeHUh?=
DSH1	MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIGxSlFKSzVyPUCuN\|g3OzFizszN	NG[wOGlUSU6JRWK=
LS-1034	M2HCd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rlSGlEPTB;MD6zPFk2PCEQvF2=	NYDT[o1sW0GQR1XS
LB373-MEL-D	NUfsT2xCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFi5T4RKSzVyPUCuN\|kyQTdizszN	M2HjcHNCVkeHUh?=
GOTO	M{PUVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHLXItHUUN3ME2wMlQzOTF6IN88US=>	M1HqUXNCVkeHUh?=
MRK-nu-1	NYXLUIlpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULqSlZqUUN3ME2wMlQzOjB3IN88US=>	NX3XXWJrW0GQR1XS
SK-MM-2	Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;RTWM2OD1yLkSzOFQzKM7:TR?=	NHPkXVJUSU6JRWK=
BOKU	M{HVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLQ[FlKSzVyPUCuOFM4QTJizszN	NUO4UXdzW0GQR1XS
NOMO-1	MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7hV2ZPUUN3ME2wMlQ{QDZizszN	NYDhbWRMW0GQR1XS
J-RT3-T3-5	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7DTWM2OD1yLkS0PFc5KM7:TR?=	MXPTRW5ITVJ?
COLO-668	NGXCOVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\vTGlEPTB;MD60OVY3QCEQvF2=	NX\2ZmNmW0GQR1XS
SF539	NFfVc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\IfWlEPTB;MD60PFY5PCEQvF2=	NFryVmxUSU6JRWK=
LB2518-MEL	M2DxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3BXFBKSzVyPUCuOFk4ODNizszN	Mn;FV2FPT0WU
TE-441-T	NVvWUWR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTBwNUCxNkDPxE1?	NYXuZoF5W0GQR1XS
MDA-MB-134-VI	NX30[HRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPxPFFKSzVyPUCuOVA6OjFizszN	MULTRW5ITVJ?
SCC-3	NYXTe4pbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTBwNUG4O\|Mh\|ryP	NYiweFNzW0GQR1XS
KLE	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTBwNUKxO\|Eh\|ryP	MXLTRW5ITVJ?
LB2241-RCC	NF;TXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGm1R2ZKSzVyPUCuOVI2OjVizszN	MnnkV2FPT0WU
NCI-H1417	M{e1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTBwNUO0N\|Uh\|ryP	NFPFUpJUSU6JRWK=
NCI-H2081	M2fvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTBwNUi2NVEh\|ryP	M4SyXXNCVkeHUh?=
NCI-H1522	MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NELIOnpKSzVyPUCuOVk{QDNizszN	NW\nTWRSW0GQR1XS
NCI-H889	M1nDbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYX2bG46UUN3ME2wMlU6QDR2IN88US=>	M13veXNCVkeHUh?=
CGTH-W-1	NV20WVc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTjTWM2OD1yLk[wO\|U2KM7:TR?=	Mln1V2FPT0WU
EB-3	M4TJdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;XeG1KSzVyPUCuOlEyPTNizszN	MWDTRW5ITVJ?
D-336MG	NF\EfZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnoXppKSzVyPUCuOlE4QTFizszN	MXHTRW5ITVJ?
LC-1F	NWL5XlJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHvdZRKSzVyPUCuOlI2QTJizszN	NEPzOlhUSU6JRWK=
MHH-NB-11	NEHsPJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\JU2lEPTB;MD62N\|gxOSEQvF2=	NYn4RZFsW0GQR1XS
SK-N-FI	NX3wWIVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrSTWM2OD1yLk[zPVEh\|ryP	M{K5VnNCVkeHUh?=
NCI-H69	NY\RfJE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fjc2lEPTB;MD62OFg4QSEQvF2=	NE\QTI5USU6JRWK=
SCH	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTBwNk[wNlMh\|ryP	Mn\HV2FPT0WU
LS-513	NIrkenFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTBwNkeyOVkh\|ryP	MnzTV2FPT0WU
CP67-MEL	NILJW5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTBwNke1PVYh\|ryP	MUjTRW5ITVJ?
GCIY	MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjnRmE1UUN3ME2wMlcxOzZ\|IN88US=>	NGLO[3hUSU6JRWK=
SHP-77	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTBwN{C3N\|Qh\|ryP	NVjHXoJWW0GQR1XS
EHEB	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2f0R2lEPTB;MD63NVg2PCEQvF2=	NUXLOHdNW0GQR1XS
D-247MG	M3ruRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\ofoFKSzVyPUCuO\|MzOzJizszN	NYHUZ3NEW0GQR1XS
Raji	M1j1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTBwN{S5PFkh\|ryP	M3H3fnNCVkeHUh?=
MPP-89	M1fub2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLuTWM2OD1yLke1PVc5KM7:TR?=	MYHTRW5ITVJ?
EKVX	M4jGS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTBwN{mwO\|Mh\|ryP	M4fCenNCVkeHUh?=
HCC2218	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVj6coxxUUN3ME2wMlc6OTNzIN88US=>	MkPSV2FPT0WU
KNS-81-FD	NV:z[ms5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTBwOEGwNVEh\|ryP	M1vnRnNCVkeHUh?=
HCC2157	MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonlTWM2OD1yLki0PVUyKM7:TR?=	NV30cHoxW0GQR1XS
BT-474	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkL3TWM2OD1yLki4PFU1KM7:TR?=	M4fx[HNCVkeHUh?=
NCI-H748	NWLlZVc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nITGlEPTB;MD65NVIh\|ryP	NXnTe2dFW0GQR1XS
EW-24	MojMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7zfIdKSzVyPUCuPVIxODJizszN	MXnTRW5ITVJ?
D-263MG	Ml72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\XS4pYUUN3ME2wMlk1PTF{IN88US=>	MXfTRW5ITVJ?
OMC-1	M2D4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTBwOU[zO\|Mh\|ryP	M1znZnNCVkeHUh?=
NCI-H2196	NWfTR4l[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmH1TWM2OD1yLkm3O\|c4KM7:TR?=	MUTTRW5ITVJ?
HAL-01	NUPYd\|VET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn6yTWM2OD1yLkm5PFczKM7:TR?=	MoriV2FPT0WU
NCI-H2107	M3XwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1m3S2lEPTB;MT6wNVg2PCEQvF2=	M4PJZ3NCVkeHUh?=
LB996-RCC	NVnIXlloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHr4[pBKSzVyPUGuNFgxPTFizszN	NVLKZWlyW0GQR1XS
NCI-H1395	MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnDTWM2OD1zLkGwOlch\|ryP	NHT6cXRUSU6JRWK=
CHP-126	MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTFwMU[xPVkh\|ryP	MoHKV2FPT0WU
NB69	M1\3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml72TWM2OD1zLkK2NVQ5KM7:TR?=	NVjiWZZsW0GQR1XS
CAS-1	NIPudGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHtOG17UUN3ME2xMlM1OjNzIN88US=>	MUfTRW5ITVJ?
JVM-3	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jhNmlEPTB;MT60O\|g2PSEQvF2=	NXjUNoNnW0GQR1XS
DMS-153	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NES3ZlFKSzVyPUGuOVc3PzRizszN	MlHTV2FPT0WU
SK-MEL-2	MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTFwN{G3PFkh\|ryP	NYrKO5FpW0GQR1XS
NCI-H1155	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTFwN{O2O\|Yh\|ryP	MX\TRW5ITVJ?
NCI-H1092	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPXZ2VKSzVyPUGuO\|YyQDJizszN	MoHvV2FPT0WU
LU-165	NWjlNWpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTFwOE[0O\|Yh\|ryP	NH:0O41USU6JRWK=
HL-60	NGDtU\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHr3c4xKSzVyPUGuPVk6ODhizszN	NF;rboVUSU6JRWK=
REH	NIm2b2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1Thd2lEPTB;Mj6wNFU5OiEQvF2=	NX:zU4ZCW0GQR1XS
JVM-2	MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHG4WVRKSzVyPUKuNFYyOzVizszN	M{TXXnNCVkeHUh?=
MN-60	NEfYepFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFfQSmNKSzVyPUKuNVc{ODhizszN	MYjTRW5ITVJ?
SCC-15	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLrTWM2OD1{LkKwNlch\|ryP	NYHMV\|dJW0GQR1XS
SNU-C1	M{\4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mle4TWM2OD1{LkKxN\|Q{KM7:TR?=	NITpTnpUSU6JRWK=
SK-MEL-1	Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVn6Z5B[UUN3ME2yMlMzODR5IN88US=>	NEPOcXNUSU6JRWK=
TGW	NHvWW2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LFfGlEPTB;Mj6zOVAzPyEQvF2=	MkDzV2FPT0WU
CA46	NHjrV5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTJwN{W5Olch\|ryP	M3rOXHNCVkeHUh?=
NCI-H23	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnteZBmUUN3ME2yMlgxPzlzIN88US=>	MWTTRW5ITVJ?
MMAC-SF	NUPVZpgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPVNI9KSzVyPUKuPFY3OjhizszN	MoHuV2FPT0WU
NCI-H2171	NIHUZo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrZTWM2OD1\|LkCzOFQ5KM7:TR?=	NIHxXIhUSU6JRWK=
A704	Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDlTWM2OD1\|LkG0NVk1KM7:TR?=	NIeye4VUSU6JRWK=
DB	M4ewWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\PTWM2OD1\|LkK1OVc3KM7:TR?=	MV3TRW5ITVJ?
NCI-H719	M1n1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTNwM{CzPFQh\|ryP	M1XuR3NCVkeHUh?=
MC-CAR	NWXXeVF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\vTWM2OD1\|LkW0PFE4KM7:TR?=	M4rXTHNCVkeHUh?=
SIMA	MmOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnVTWM2OD1\|LkW4OFE3KM7:TR?=	MVPTRW5ITVJ?
SW872	NVLl[FVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnn5TWM2OD1\|Lke4NVAyKM7:TR?=	MYnTRW5ITVJ?
HCC1187	MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHQTWM2OD1\|Lke4N\|E2KM7:TR?=	MU\TRW5ITVJ?
EW-13	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWqwPZRvUUN3ME2zMlg{PDF5IN88US=>	M3jOVXNCVkeHUh?=
NCI-SNU-1	NUHESlFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTRwMkG5PVkh\|ryP	NHLiO3BUSU6JRWK=
NCI-H226	M2TqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonCTWM2OD12LkOzOlA3KM7:TR?=	MlvzV2FPT0WU
RPMI-8866	M4jYbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEfNRWRKSzVyPUSuN\|YxOjlizszN	NVnCN\|V1W0GQR1XS
OCI-AML2	MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLaTWM2OD12LkW1NlMh\|ryP	M3\ZVXNCVkeHUh?=
LU-65	M1u2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDI[ZpKUUN3ME20Mlk{ODN\|IN88US=>	MXHTRW5ITVJ?
SK-N-DZ	MknQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTVwNkO0OlUh\|ryP	NH[4N\|dUSU6JRWK=
NB14	NVX1co1XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLTZ2U2UUN3ME21Mlk4OTN3IN88US=>	M3iwVXNCVkeHUh?=
COLO-829	NGLFTZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE[2XFNKSzVyPU[uN\|M{PTlizszN	NY\YcmRbW0GQR1XS
MHH-CALL-2	M3zVTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTZwNUG1NFgh\|ryP	MlPTV2FPT0WU
NCI-H1770	NUnaN5RyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoH1TWM2OD14Lk[2PVA1KM7:TR?=	M1LBUHNCVkeHUh?=
ECC4	NF7D[JZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrYTWM2OD14LkiyNVc6KM7:TR?=	MXHTRW5ITVJ?
A498	NVizeVc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTZwOEexPVIh\|ryP	Mnq0V2FPT0WU
DMS-79	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFSwTolKSzVyPUeuNFQ2OTJizszN	MWDTRW5ITVJ?
P30-OHK	NWKxXJRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2n3UGlEPTB;Nz6yNVkxPiEQvF2=	NUHOVGhPW0GQR1XS
D-502MG	M4DJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTdwOUizOkDPxE1?	MonKV2FPT0WU
RCC10RGB	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRThwME[yPEDPxE1?	MXTTRW5ITVJ?
U-698-M	MmjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXaXJVKSzVyPUiuNlkzOjZizszN	NVnVZnZrW0GQR1XS
BB49-HNC	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3P0XmlEPTB;OT60NlI3PSEQvF2=	NXPOfHpqW0GQR1XS
ES1	NXnKOpdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXtTFl1UUN3ME25MlY5QTV4IN88US=>	NWK0[pF7W0GQR1XS
MFM-223	NEHIZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\VTWM2OD1zMD65PVI4KM7:TR?=	NH7NWXVUSU6JRWK=
C2BBe1	NY\2WllVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnfxTWM2OD1zMT6zOVI{KM7:TR?=	NFnmdGFUSU6JRWK=
EB2	M1SycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\J[WlEPTB;MUKuOlg5OSEQvF2=	NUXieZg2W0GQR1XS
C8166	Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzsTWM2OD1zMz64N\|A{KM7:TR?=	NXrz[21tW0GQR1XS
ES3	NV;YdHV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33xc2lEPTB;MUOuPVk4PyEQvF2=	M1;hTHNCVkeHUh?=
NCI-H1650	NETlTZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDqVmNkUUN3ME2xOk4{PzZ3IN88US=>	MUXTRW5ITVJ?
Mo-T	NF3mWHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\ad2lEPTB;MUeuOFAzQSEQvF2=	MkLPV2FPT0WU
NB7	NGTQUWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVT5OHRLUUN3ME2xO{44PDZ5IN88US=>	NIXyNWVUSU6JRWK=
ES7	NX\OUXZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1fLcWlEPTB;MUmuOVUxPyEQvF2=	Mn3aV2FPT0WU
ES5	NHzVc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTJzLke2O\|Eh\|ryP	Ml;rV2FPT0WU
MSTO-211H	NWTX[W5oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37JPGlEPTB;MkGuPFg2QCEQvF2=	NVPyRpd6W0GQR1XS
U-87-MG	NHTpb4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPqPIx5UUN3ME2yOU4yQTZ4IN88US=>	M4K5UnNCVkeHUh?=
THP-1	M33XUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLsOFVKUUN3ME2yPU44OjBzIN88US=>	NFP3THBUSU6JRWK=
NB10	NVrwNmZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jUS2lEPTB;M{CuNlY6PCEQvF2=	NE\mbWVUSU6JRWK=
NH-12	MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTN\|LkKwNVch\|ryP	M4rpcXNCVkeHUh?=
COLO-824	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfTTWM2OD1\|ND6xNFA3KM7:TR?=	MnnpV2FPT0WU
SKM-1	NEDRWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPyUFVKSzVyPUO3Mlg1OjJizszN	Mn7PV2FPT0WU
NCI-H1838	Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXz2UpJMUUN3ME2zPE4{Pzl5IN88US=>	M4HnenNCVkeHUh?=
RL	M3HTUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjBTWM2OD1\|OT6yOFc4KM7:TR?=	M2nsOnNCVkeHUh?=
COLO-800	MoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7ITWM2OD12MD6wO\|c{KM7:TR?=	NGnvVWhUSU6JRWK=
KG-1	MmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3:2d2lEPTB;NECuPFk2PSEQvF2=	NH20UZBUSU6JRWK=
TUR	NGTlO\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTRzLk[zPVkh\|ryP	MoO1V2FPT0WU
LNCaP-Clone-FGC	M3fLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDOdpdKSzVyPUSxMlkxOTdizszN	MWTTRW5ITVJ?
NCI-H322M	NVXS[o5NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrUVYhJUUN3ME20Nk42QTh2IN88US=>	MoPLV2FPT0WU
LNCaP	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLyfldnUUN3ME25NU4{KG6P	NWTiXYozOjV3MEWxO\|Q>
C4-2	NWXxNXNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRThibl2=	NHXWZXozPTVyNUG3OC=>
JURKAT	NU\HfZF7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUGyOEBp		MmnmTWM2OD12MU[uOlYhdk1?	M135d\|I1PTF7OUm1
MOLT-4	NE\NRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoDBNlQhcA>?		MoCzTWM2OD1{OEWzMlUhdk1?	NXP2SIxkOjR3MUm5PVU>
REH	NWHUOYIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWCyOEBp		MVHJR\|UxRTJ6Nz62PEBvVQ>?	Mo\sNlQ2OTl7OUW=
NALM-6	NYfscYdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXmyOEBp		NUHpe\|I2UUN3ME2zOFM{OCCwTR?=	M1LqSlI1PTF7OUm1
RS 4;11	NFSxOFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mkm0NlQhcA>?		MUnJR\|UxRTVzOT6wOUBvVQ>?	NGr0NJQzPDVzOUm5OS=>
697	NUHRcYg2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2q1VlI1KGh?		MYjJR\|UxRTJzMEeuNUBvVQ>?	MXiyOFUyQTl7NR?=
SIL-ALL	NF7wNoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4ThTVI1KGh?		MWXJR\|UxRTF7OT63O{BvVQ>?	Mn7zNlQ2OTl7OUW=
CEM	Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEO0b\|IzPCCq		MX\JR\|UxRTV{LkG4JI5O	NFflfJozPDVzOUm5OS=>
P12	M2jFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2Dn[FI1KGh?		MYDJR\|UxRTN7LkK3JI5O	MWWyOFUyQTl7NR?=
NALM-16	M1z2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2raeFI1KGh?		MmHrTWM2OD17Nj6yPEBvVQ>?	Mlm0NlQ2OTl7OUW=
JURKAT	M2rnWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWG0PEBp		MlXiTWM2OD1zND64OEBvVQ>?	NVX4fpVmOjR3MUm5PVU>
MOLT-4	NYDkOFJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnnROFghcA>?		M321N2lEPTB;Mk[uOkBvVQ>?	NXG2[2NVOjR3MUm5PVU>
REH	NFThPGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVy0PEBp		MojLTWM2OD12ND63NUBvVQ>?	MYOyOFUyQTl7NR?=
NALM-6	M2HNO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1THZlQ5KGh?		NIrEdHpKSzVyPUKzMlI3KG6P	NX;DbHY5OjR3MUm5PVU>
RS 4;11	MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4LXb\|Q5KGh?		NIPhcJBKSzVyPUG2OE4zQCCwTR?=	MVKyOFUyQTl7NR?=
697	NFzWdphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{nENFQ5KGh?		Mof2TWM2OD1\|MEWuN{BvVQ>?	Mnv2NlQ2OTl7OUW=
SIL-ALL	NGXITGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4GwPVQ5KGh?		MmrwTWM2OD15ND62NkBvVQ>?	M1fDVFI1PTF7OUm1
CEM	NYDscIZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGewN4M1QCCq		M4G4SmlEPTB;MkSuOVUhdk1?	MoD0NlQ2OTl7OUW=
P12	M1LXUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3XPOlQ5KGh?		MYjJR\|UxRTF6LkS2JI5O	NGHkZ3gzPDVzOUm5OS=>
NALM-16	M4npZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIe0XWk1QCCq		Ml\hTWM2OD14Mz6yOEBvVQ>?	Ml;HNlQ2OTl7OUW=
JURKAT	MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUW3NkBp		NW\iO2FJUUN3ME2zMlY2KG6P	M{\GOFI1PTF7OUm1
MOLT-4	NIfyNWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFzhV4k4OiCq		MmPZTWM2OD15LkO5JI5O	NX[5UHNPOjR3MUm5PVU>
REH	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGXBVnM4OiCq		MUPJR\|UxRTF4LkCxJI5O	NE\VNI0zPDVzOUm5OS=>
NALM-6	MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHfOc3c4OiCq		MmftTWM2OD1zLke4JI5O	M4f4bFI1PTF7OUm1
RS 4;11	NYq2NHloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIG3UJE4OiCq		NX\FeXduUUN3ME20MlM5KG6P	Ml3UNlQ2OTl7OUW=
697	NIjVdmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnnRO\|IhcA>?		MkfnTWM2OD15ND6yPEBvVQ>?	M1;wWlI1PTF7OUm1
SIL-ALL	NIPOeGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUH5boNNPzJiaB?=		M3q3bmlEPTB;Nz6yJI5O	NWfRUXQxOjR3MUm5PVU>
CEM	MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHTBSnE4OiCq		NFXQ[49KSzVyPUWuOFIhdk1?	NYDIUZR7OjR3MUm5PVU>
P12	M2S1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1PNSVczKGh?		M17nWmlEPTB;Nj6zO{BvVQ>?	MXqyOFUyQTl7NR?=
NALM-16	Ml3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXPofoVXPzJiaB?=		MWjJR\|UxRTd5LkezJI5O	NGDyXYkzPDVzOUm5OS=>
Y79	NXr5TXpmSXCxcITvd4l{KEG\|c3H5	M2HGNlEuPTBibl2=	NIXCNIsyOi9{NDDo	Ml\nSG1UVw>?	NH;NUHdqdmS3Y3XkJIFxd3C2b4Ppd{B4cGmlaDDjZY4h[mViZX7oZY5k\WRiYomgTHQ>	MYSyOFM3PjZ4NR?=
WER-Rb-1	MXrBdI9xfG:\|aYOgRZN{[Xl?	NY\kNWRGOS13MDDuUS=>	MnyzNVIwOjRiaB?=	MofoSG1UVw>?	MnfJbY5lfWOnZDDhdI9xfG:\|aYOge4hq[2hiY3HuJIJmKGWwaHHuZ4VlKGK7IFjU	M1\GUVI1OzZ4Nk[1
G7	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;TbVJKSzVyPUOuN{BvVQ>?	NUjxdGJKOjR{MES3N\|M>
G166	NHf4VHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWf6ZoQ1UUN3ME23MlAhdk1?	MUeyOFIxPDd\|Mx?=
CB660	NGGxWpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkP5TWM2OD14LkSgcm0>	NVHDRm9KOjR{MES3N\|M>
CB1117	MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo[1TWM2OD1zNT62JI5O	M4DlTVI1OjB2N{Oz
KB-3-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTFwNEigxtEhOC53MzDuUS=>	NHnUPI8zOzl4MkS0OS=>
KB-8-5-11	M4LM[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfqTWM2OD13LkCxJOKyKDJwMEGgcm0>	M{nrcFI{QTZ{NES1
KB-C-1	NIWxVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTF4Lke2JOKyKDRwNUGgcm0>	NInnN5ozOzl4MkS0OS=>
KB-V-1	NX3wTnh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHGxW5BKSzVyPUK4NU4zPCEEsTCzNU42PyCwTR?=	NXfHO5Y5OjN7NkK0OFU>
OVCAR-8	MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEHHO25KSzVyPUeuNVkhyrFiMz62NEBvVQ>?	NGHRSFYzOzl4MkS0OS=>
NCI-ADR-RES	NVTLUFUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTF{N{OuN\|AhyrFiMUmxMlIxKG6P	NUSxTmh6OjN7NkK0OFU>
MCF7	NWSybY11T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTCTWM2OD13LkGxJOKyKDFwNEegcm0>	MWeyN\|k3OjR2NR?=
MCF7-FLV1000	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M161N2lEPTB;M{mzMlE5KMLzIEe0Mlg{KG6P	M{nVSlI{QTZ{NES1
S1	MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\CcXdKSzVyPUK0MlMxKMLzIESuO\|Uhdk1?	NIXvfnIzOzl4MkS0OS=>
S1-M1-80	NHLERY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrGTWM2OD1{NkGuNFYhyrFiNEiuNlUhdk1?	NEPmW3EzOzl4MkS0OS=>
CORL-23/P	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvZTWM2OD12LkO4JOKyKDFwMkWgcm0>	NVmyc\|F[OjN7NkK0OFU>
CORL-23/R	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYfrdYhPUUN3ME21MlE3KMLzIEGuPFMhdk1?	M{nyTFI{QTZ{NES1
NIH3T3	MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\PeoRKSzVyPUSwMlYxKMLzIESuPVchdk1?	M2TZflI{QTZ{NES1
NIH3T3-G185	M33Zb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTJ2MUOuOFAhyrFiNEKzMlY3KG6P	MWWyN\|k3OjR2NR?=
pcDNA-HEK293	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTJwN{WgxtEhOC54NzDuUS=>	Mn;oNlM6PjJ2NEW=
MDR19-HEK293	NYPtdm9NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGTVboZKSzVyPUi1MlUxKMLzIEGzMlY4KG6P	Mn3RNlM6PjJ2NEW=
R482-HEK293	NVjmfnVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjHTWM2OD1{NT65O{DDuSB2Lkm1JI5O	MYSyN\|k3OjR2NR?=
MRP1-HEK293	Mn:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnNOmF6UUN3ME2yMlk6KMLzIEGuOFkhdk1?	MXiyN\|k3OjR2NR?=
SF188	NFXvcWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DBbFExNTFyMDDuUS=>	NIj0PHkzPC17NjDo	MmnDSG1UVw>?	MUjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLTDk[ZBm\GWwdDDtZY5v\XJ?	MV6yN\|g5PzZ2NR?=
T98G	NHfWcWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTUNVAuOTByIH7N	NX7yfXpZOjRvOU[gbC=>	M2rwO2ROW09?	NYDZWoFVcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZ49v[2WwdILheIlwdi1iZHXw[YRmdnRibXHucoVz	NEDVUnYzOzh6N{[0OS=>
DU145	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M320dmROW09?	NHnDdlZKSzVy4pk8OlAhdk1?	MlPCNlM5QDR2Mki=
LNCaP	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYjSVZlbTE2VTx?=	NYTPVlNRUUN3MPMIwFc2KG6P	NGHqemEzOzh6NESyPC=>
PC3	NV\2U4hGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYj5WYRyTE2VTx?=	NF2wZm5KSzVy4pk8NVc2KG6P	NYPtcIhrOjN6OES0Nlg>
RT4	NY\H[m1UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLoTWM2OD1{Nz6yNUBvVQ>?	NVPWV257OjN5OUK2N\|k>
5637	NInvd4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjmTWM2OD12NT60O{BvVQ>?	M3;yOVI{Pzl{NkO5
T24	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTd7LkGyJI5O	MWOyN\|c6OjZ\|OR?=
MCF7	M{nGfmZ2dmO2aX;uJGF{e2G7	MXyxNFAhdk1?	MX6xJIg>	NF\U[JhFVVOR	M1jUbpJm\HWlZYOgeIhmKGmwZIXjeIlwdiCxZtMgS5Jm[jFuwrDT[4syNMLiUIOyMOKhW2W{cHnuZVMtKGGwZNMgW4l{eDJ?	NIjDRmozOzd5MEK0OC=>
KB-V1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTNwOUKg{txO	MlzLNlM2QTNzOU[=
Hec50co	M2\FeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfKdZRKSzVyPUWgcm0>	M{nTWFI{OTR4Nki3
MDA-MB-468	M1LDZmFxd3C2b4Ppd{BCe3OjeR?=	NVjUR3c1OS93L{GwJI5O	NHLVU2wzPC92OD:3NkBp	M3\kfGROW09?	M1;mSIlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M1rNblI{OTR2Mkm0
MCF10A	NXXSRVBNSXCxcITvd4l{KEG\|c3H5	NHLBe48yNzVxMUCgcm0>	NWH2N4JkOjRxNEivO\|IhcA>?	NFyw[2JFVVOR	MUPpcoR2[2W\|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NFviXHYzOzF2NEK5OC=>
Huh-7	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjsc3hGOS9zMD:xNFAwOTByMDDuUS=>	Moe3OFghcA>?		M3PVb4Rm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh\G:\|ZT3k[ZBmdmSnboTsfS=>	Mk\0NlI4PDV3OEe=
Daoy	NHzJUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDTNU45PzVvMkSwJI5O	NVntTlZIPzJiaB?=	MkXqSG1UVw>?	MW\JR\|UxRTVibl2=	NGf3RoszOjN7MEK3PS=>
ONS-76	NYrJeWtUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfMNU45PzVvMkSwJI5O	NH3ERng4OiCq	NUXrNoU6TE2VTx?=	NYq3W5VCUUN3ME23MlUhdk1?	M1vYbVIzOzlyMke5
SUM 149	NGiwNnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7wZmExNTFyMDDuUS=>	NIfIdWo4OiCq		MUHpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK=	MoX4NlI{ODl7M{m=
MDA-MB-231	NIjU[\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzGNE0yODBibl2=	MkP5O\|IhcA>?		NETiSnpqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7uZZI>	NHfoepYzOjNyOUmzPS=>
HR5	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nM[\|AuOTByIH7N	NGftd2E4OiCq		MWrpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK=	NHzld4wzOjNyOUmzPS=>
BT-474-M1	NFHjTYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3H5OFAuOTByIH7N	NV3KU5RvPzJiaB?=		M{fOTYlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=>	NX3RO2p5OjJ\|MEm5N\|k>
AU565	NESyc\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\r[VAuOTByIH7N	NHzKWpM4OiCq		NV3mT49tcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz	MYeyNlMxQTl\|OR?=
T47D	NXm5O2ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7YU5dQOC1zMECgcm0>	M16wSVczKGh?		M3TFdYlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=>	MknHNlI{ODl7M{m=
MCF7	NHz1VphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETPTlAxNTFyMDDuUS=>	MWG3NkBp		M{jo[4lvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=>	Mm[3NlI{ODl7M{m=
HCT116p53(+/+)	NELSdWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfuRoliOTBvMUCwNEBvVQ>?	MUGyOE81QCCq		MUXpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gZ49ueGyndHXsfUBifCB{NTDuUS=>	NInNcnczOjJ4MkG3NS=>
HCT116p53(-/-)	M2mzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUT0cVU2OTBvMUCwNEBvVQ>?	M1PLSFI1NzR6IHi=		MVjpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gZ49ueGyndHXsfUBifCB{NTDuUS=>	NFTwVHAzOjJ4MkG3NS=>
HeLa	MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;WTI9COTBvMUCwJI5O	M3PxNFQ5KGh?	NUTWdWxWTE2VTx?=	M1;jTmlEPTB;NUKuPUBvVQ>?	MXWyNlA5ODJ\|NR?=
HeLa	NWP3epJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFSwOoUyOC1zMECgcm0>	NF71Zo04OiCq	MX7EUXNQ	NUO0R5I2UUN3ME21NE42KG6P	NY\yPJBSOjJyOECyN\|U>
GBC	M2DQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYX0SY5xPzJiaB?=		MWfJR\|UxRTF2Lke4JI5O	M2XPSVIyQTZ3N{O5
GB-CL-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoftO\|IhcA>?		MXnJR\|UxRTVwMkKgcm0>	NIrXOoYzOTl4NUezPS=>
Mz-ChA-2	NFTicotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUjMWIhiPzJiaB?=		M171fWlEPTB;Mz6zNUBvVQ>?	MV6yNVk3PTd\|OR?=
TGBC1-TKB	Mmj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2fxUlE1PCCq		MYTJR\|UxRTZwN{Kgcm0>	NXHPdlU6OjF7NkW3N\|k>
Wittier	M3\CUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkXpO\|IhcA>?		MXPJR\|UxRTNwMk[gcm0>	Mm\BNlE6PjV5M{m=
H-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mor6O\|IhcA>?		NWXxe4diUUN3ME25MlU1KG6P	NGH1cWszOTl4NUezPS=>
HuH-28	M1jkXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4GzdVczKGh?		MUfJR\|UxRTFzLkG5JI5O	MnXpNlE6PjV5M{m=
NEC	MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnvDO\|IhcA>?		MoHHTWM2OD17Lkm4JI5O	NVTHdIhIOjF7NkW3N\|k>
REB	NH7NVXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mn3qO\|IhcA>?		MnvYTWM2OD1zMz61NUBvVQ>?	NHrE[5IzOTl4NUezPS=>
CC-LP-1	M2Twb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3XkfVczKGh?		MkPHTWM2OD13Lki0JI5O	NIPsVWUzOTl4NUezPS=>
CC-SW-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXO3NkBp		NXXjfVRxUUN3ME25MlU2KG6P	NHvtWXgzOTl4NUezPS=>
EGI-1	NILRNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NX\qfFl2PzJiaB?=		NGP3b21KSzVyPUGwMlczKG6P	MVOyNVk3PTd\|OR?=
Sk-ChA-1	MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXO3NkBp		MVXJR\|UxRTF5LkKgcm0>	M17aTVIyQTZ3N{O5
TFK-1	M1;CVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4TGcVczKGh?		MnPMTWM2OD1zMz60OUBvVQ>?	NVL3eHMxOjF7NkW3N\|k>
786-O	MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zGSVUuQDBibl2=	MYm5OkBp	MXHIR4w>	NXvFTJVme3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N	M2THVFIyPjR{M{e0
A498	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXO1MVgxKG6P	MojQPVYhcA>?	NUjNSGJ7UEOu	NETHb4l{fXCycnXzd4V{KHSqZTDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKHerdHigTWM2OMLidnHseYV{KG:oIEKgeI8hOjBibl2=	MlXmNlE3PDJ\|N{S=
ACHN	NEm4UolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETtc5Y2NThyIH7N	MnzQPVYhcA>?	Mm\uTGNt	NEj5dHl{fXCycnXzd4V{KHSqZTDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKHerdHigTWM2OMLidnHseYV{KG:oIEKgeI8hOjBibl2=	M17CXFIyPjR{M{e0
Caki-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXL6T3Y3PS16MDDuUS=>	NFHqeFc6PiCq	MWPIR4w>	MnHxd5VxeHKnc4Pld{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkB4cXSqIFnDOVDDqH[jbIXld{Bw\iB{IITvJFIxKG6P	MYmyNVY1OjN5NB?=
SN12C	MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWi1MVgxKG6P	M{Tpblk3KGh?	MVPIR4w>	MnnId5VxeHKnc4Pld{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkB4cXSqIFnDOVDDqH[jbIXld{Bw\iB{IITvJFIxKG6P	M4fleVIyPjR{M{e0
HMC-1.1	M1ryVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDuVWgyNTFyMECgcm0>	NEXMUnQ4OiCq		M3PYeolvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\Q>?	MmqzNlEzPDJzOEm=
HMC-1.2	M1PqS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnKzNU0yODByIH7N	Ml3NO\|IhcA>?		NU[ybHd6cW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6n	MWqyNVI1OjF6OR?=
C2	M13HNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jVfFEuOTByMDDuUS=>	Mk\hO\|IhcA>?		M2DsdIlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\Q>?	NU\xR5ptOjF{NEKxPFk>
CHP-212	NEXDRZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rVNFEuOTJ3IH7N	MW[yOE0yOjBiaB?=		MoHxbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?=	MWOyNVE3QTJ2Mh?=
IMR-32	NFzIRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\PNU0yOjVibl2=	NUDYZXVTOjRvMUKwJIg>		NYXmVHRwcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=>	MYqyNVE3QTJ2Mh?=
Kelly	NEXzcWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXMS40yNTF{NTDuUS=>	MWSyOE0yOjBiaB?=		NHThXVNqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	M3nB[lIyOTZ7MkSy
SH-EP	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkO0NU0yOjVibl2=	MlTMNlQuOTJyIHi=		MXjpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	M4OyXVIyOTZ7MkSy
SH-SY5Y	NHLVXVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLJPI5QOS1zMkWgcm0>	MUWyOE0yOjBiaB?=		M3;uZYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW=	NEDZV2czOTF4OUK0Ni=>
SK-N-AS	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPWTIUyNTF{NTDuUS=>	NHzoe4kzPC1zMkCgbC=>		MX7pcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	MY[yNVE3QTJ2Mh?=
SK-N-BE	M4nWPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVSxMVEzPSCwTR?=	M{Xob\|I1NTF{MDDo		MXzpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	NIr2[XEzOTF4OUK0Ni=>
KG1	NVzqSINQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfhNpcyNzFyL{GwNEBvVQ>?	M134[\|czKGh?	NVfPWI9PTE2VTx?=	MknUbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?=	NWrZS21lOTl2NUizOVg>
U937	NYjFdZRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUj0UJFoOS9zMD:xNFAhdk1?	MofFO\|IhcA>?	M2HDb2ROW09?	NHe0VFNqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	NXPMXHVnOTl2NUizOVg>
CAL62	M3Hwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\PdXpuOC5zLUGwNEBvVQ>?	NWOz[4FFPzJiaB?=	M{\BZmROW09?	NHLOeJlGSzVyPUGuOEBvVQ>?	M1zWZ\|E6OjJ\|NUWz
OCUT-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV6wMlEuOTByIH7N	Mm\3O\|IhcA>?	MWDEUXNQ	M4DSTWVEPTB;Mj6zJI5O	NXfGbmhROTl{MkO1OVM>
8505C	M3PKdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWKwMlEuOTByIH7N	NXrQeIFvPzJiaB?=	M1H3RmROW09?	M4PSTWVEPTB;Mz6yJI5O	Mn\JNVkzOjN3NUO=
ACT-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjMNnlpOC5zLUGwNEBvVQ>?	MXO3NkBp	M1\JfWROW09?	M3z4R2VEPTB;NT60JI5O	NVPVRnRYOTl{MkO1OVM>
SW1736	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUSwMlEuOTByIH7N	NEjZWmc4OiCq	Ml;lSG1UVw>?	NHziTGpGSzVyPUWuOkBvVQ>?	MlPMNVkzOjN3NUO=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pro-caspase-8 / cleaved caspase-8 / cleaved caspase-3 / cleaved caspase-9; PubMed: 27699933 Cancer Sci PLKi‐induced caspase activation. HeLa cells were treated with BI 2536 (10 nmol/L), BI 6727 (68 nmol/L), or GSK461364 (11 nmol/L), and HCT 116 cells were treated with BI 2536 (20 nmol/L), BI 6727 (70 nmol/L), or GSK461364 (12 nmol/L) for 48 h. The levels of cleaved caspase (CASP)‐3, ‐8, and ‐9 were examined by Western blot analysis. p-HH3 / PARP / Myc / p-Myc; PubMed: 24771642 Clin Cancer Res Western blotting showing more mitotic arrested (shown by phospho-histone H3) and apoptotic (shown by PARP) cells as well as lower MYC levels in LNCaP-Pim1 cells after BI 2536 treatment compared with LNCaP-Neo cells. The difference is obvious at lower dose of BI 2536 (10 nM). Both total MYC expression and phosphor-MYC levels were lower in Pim1 cells than Neo cells after BI 2536 treatment. pMEK / MEK / pERK / ERK / pRSK1 / RSK1; PubMed: 28430578 Oncotarget (A) and (B) Western blot analysis of the expression and activation of components of the MEK-ERK-RSK1 pathway in MKN45 and MKN74 cancer cells treated with BI 2536 and BI 6727 for 24 and 48 hours, respectively. pPlk1 / Plk1 / pMyt1; PubMed: 28430578 Oncotarget (A) and (B) Western blot analysis of the expression and phosphorylation of Plk1, and phosphorylation of Myt1 in the CSC-like and cancer cells after treatment with BI 2536 and BI 6727 for 24 and 48 hours, respectively. Aurora B / pAurora B / pAurora C / pH3 / Cyclin B1 / Securin / pBcl-XL / MPM2; PubMed: 25169932 Mol Oncol Western blot analysis of cells treated for 24 h with the indicated inhibitor concentrations. Cell lysates were immunoblotted for Plk1, Phospho-Aurora B (T232)/Aurora C (T198), Aurora B, histone H3 phosphorylated at S10 (pH3), Cdk1, Cyclin B1, Securin, Phospho-Bcl-XL, Induced myeloid leukemia cell differentiation protein Mcl-1, MPM-2 and β-Actin. Left (Hela cells); Right (HUVEC)	27699933 24771642 28430578 25169932
Immunofluorescence	p-H2AX / propidium iodide; PubMed: 22309939 Breast Cancer Res Apoptotic images of the cells after BI 2536 treatment, as revealed by HCS (high-content screening) instrument (×10) with phospho-H2AX antibody or PI (propidium iodide) intake. Pericentrin / α-tubulin; PubMed: 21772266 Nat Commun MEFs were labelled using Plk1, pericentrin and α-tubulin antibodies and 4,6-diamidino-2-phenylindole for the analysis by immunofluorescence microscopy. Representative examples of BI 2536-treated and control MEFs are depicted. Scale bar, 5 μm.	22309939 21772266
Growth inhibition assay	Cell viability; PubMed: 21772266 Nat Commun Proliferative activity of MEFs at different BI 2536 concentrations (25–250 nM; means±s.d., n=3, for each concentration). P<0.05, P<0.01, **P<0.001, Student's t-test, unpaired and two-tailed.	21772266

In vivo

BI 2536 given i.v. once or twice per week is highly efficacious in diverse xenograft models with acceptable tolerability by inhibiting cell proliferation through a mitotic arrest, and subsequently induction of tumor-cell death. Administration of BI 2536 at 50 mg/kg once or twice per week significantly inhibits growth of HCT 116 xenografts with T/C of 15% and 0.3%, respectively. BI 2536 treatment twice-weekly also leads to excellent tumor-growth in BxPC-3 and A549 models with T/C of 5% and 14%, respectively. ^[1]

Protocol

Kinase Assay:^[1]	- Collapse Plk1 in vitro kinase assay: Recombinant human Plk1 (residues 1-603) is expressed as N-terminal, GST-tagged fusion protein with a baculoviral expression system and purified by affinity chromatography with Glutathione-agarose. Enzyme activity assays for Plk1 are performed in the presence of serially diluted BI 2536 with 20 ng of recombinant kinase and 10 μg casein from bovine milk as the substrate. Kinase reactions are performed in a final volume of 60 μL for 45 minutes at 30 °C (15 mM MgCl₂, 25 mM MOPS [pH 7.0], 1 mM DTT, 1% DMSO, 7.5 mM ATP, 0.3 μCi γ-³³P-ATP). Reactions are terminated by the addition of 125 μL of ice-cold 5% TCA. After transfer of the precipitates to Multi-Screen mixed ester cellulose filter plates, plates are washed with 1% TCA and quantified radiometrically. Dose-response curve is used for calculating IC50 value.
Cell Research:^[1]	- Collapse Cell lines: HeLa, A43, SKOV-3, HT-29, K562, A549, Saos-2, MCF7, HCT116, COLO 205, Hep G2, Raji and PC-3 cells, etc. Concentrations: Dissolved in DMSO, final concentrations ~1 μM Incubation Time: 24 and 72 hours Method: Cells are exposed to various concentrations of BI 2536 for 24, and 72 hours. Cell growth is assessed by the measurement of Alamar Blue dye conversion in a fluorescence spectrophotometer. For determining the DNA content of the cultures, cell suspensions are fixed in 80% ethanol, treated for 5 minutes with 0.25% Triton X-100 in PBS, and incubated with 0.1% RNase and 10 μg/mL propidium iodide (PI) in PBS for 20 minutes at RT. Cell-cycle profiles are determined by flow cytometric analysis. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Female BomTac:NMRI-Foxn1^nu mice injected subcutaneously with HCT 116, NCI-H460, or A549 cells Formulation: Formulated in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl Dosages: ~50 mg/kg Administration: Injection i.v. once or twice per week (Only for Reference)

References

Solubility (25°C)

In vitro	Ethanol	100 mg/mL (191.69 mM)
	DMSO	21 mg/mL (40.25 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG 400+0.5% Tween 80+5% Propylene glycol For best results, use promptly after mixing.	15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BI 2536 SDF

Molecular Weight	521.66
Formula	C₂₈H₃₉N₇O₃
CAS No.	755038-02-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02215044	Terminated	Drug: BI 2536 intravenous\|Drug: Gemcitabine intravenous	Pancreatic Neoplasms	Boehringer Ingelheim	June 2007	Phase 1
NCT02211833	Completed	Drug: BI 2536\|Drug: Pemetrexed	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	October 2006	Phase 1
NCT00701766	Completed	Drug: BI 2536	Leukemia Myeloid Acute	Boehringer Ingelheim	October 2006	Phase 2
NCT00706498	Completed	Drug: BI 2536	Prostatic Neoplasms	Boehringer Ingelheim	September 2006	Phase 2
NCT00376623	Completed	Drug: BI 2536	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	July 2006	Phase 2
NCT02211872	Completed	Drug: BI 2536 BS intravenous	Neoplasms	Boehringer Ingelheim	August 2004	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
We need to use BI 2536 in preclinical studies using mice, how to formulate the inhibitor for this in vivo study?
Answer:
For in vivo study, DMSO should not be more than 5% because the toxicity. You can formulated BI2536 in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl for animal study according to the reference :( Supplemental Data) http://linkinghub.elsevier.com/retrieve/pii/S0960-9822(06)02671-6

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

Selective Plk Inhibitors

GSK461364 : Plk1-selective, K_i=2.2 nM.
Plk Inhibitor in Clinical Trial

Rigosertib (ON-01910) : Phase III for Myelo Dysplastic Syndrome (MDS).
Newest Plk Inhibitor

Ro3280 ^New : Potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.
Calssic Plk Inhibitor

Volasertib (BI 6727) : Highly potent Plk1 inhibitor with IC50 of 0.87 nM and in phase II trials.

Related PLK Products

SBE 13 HCl ^New

SBE 13 HCl is a potent and selective PLK1 inhibitor with IC50 of 200 pM, >4000-fold selectivity over Aurora A kinase, Plk2 and Plk3.
Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
Rigosertib (ON-01910)

Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Phase 3.
HMN-214

HMN-214 is a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.
GSK461364

GSK461364 inhibits purified Plk1 with K_i of 2.2 nM in a cell-free assay. It is more than 1000-fold selective against Plk2/3. Phase 1.

Features:Demonstrates >390-fold selectivity for Plk1 relative to Plk2 and Plk3.
Volasertib (BI 6727)

Volasertib (BI 6727) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Phase 3.

Features:A high volume of distribution, indicating good tissue penetration, and a long terminal half-life.
MLN0905

MLN0905 is a potent inhibitor of PLK1 with IC50 of 2 nM.
Ro3280

RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

Features:A selective PLK1 inhibitor. Demonstrates greater potency than BI2536. Potential use in nasopharyngeal carcinomas.
NMS-P937 (NMS1286937)

NMS-P937 (NMS1286937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. Phase 1.

Choose Your Country or Region

By Signaling Pathways

By product type

BI 2536

Cited by 131 Publications

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BI 2536 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

Related PLK Products

Choose Your Country or Region

By Signaling Pathways

By product type

BI 2536

Cited by 131 Publications

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BI 2536 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

Related PLK Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)